Broad molecular profiling for targeted cancer care

Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge.

The InVision™ proprietary platform is a tagged-amplicon sequencing (TAm-Seq™) method, which allows amplification and deep sequencing of genomic regions spanning thousands of bases from individual copies of fragmented DNA.

InVision

Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge.

Plasma collection DNA extraction
ctDNA
analysis
Bioinformatics analysis
Oncology report generated

When analyzed with Inivata’s propriety algorithms and database, this can be used to generate a detailed report, providing critical insights into the patient’s tumor profile.

Stand-out sensitivity

InVision™ has been developed to provide an exceptional level of sensitivity, while retaining a comprehensive coverage.

>99% of mutations at >0.5% Allele Frequency

A clinically focused, comprehensive, all classes of alterations, liquid biopsy tumor profiling panel designed for molecular stratification in cancer patients when tissue is unavailable

  ALK
AKT1
BRAF
CCND1
CDKN2A
CTNNB1
  EGFR
  ERBB2
ESR1
  FGFR1
FGFR2
FGFR3
GATA3
GNA11
GNAQ
GNAS
HRAS
IDH1
IDH2
KIT
KRAS
MAP2K1
  MET
MYC
NFE2L2
NRAS
NTRK1
NTRK3
PDGFRA
PIK3CA
PPP2R1A
PTEN
  ROS1
STK11
TP53
U2AF1
SNVs + Indels - Exon Coverage 70% for PTEN, 88-100% for TP53, STK11 and CDKN2A
SNVs + Indels - Hotspot Regions
Fusions + SNVs + Indels
CNVs + SNVs + Indels
CNVs only

Please contact us for further information.